ETC-501 / A*Star - LARVOL DELTA

MNK2-dependent activation of de novo lipid synthesis drives breast cancer brain metastasis (AACR 2025) - "Our study reveals a critical role for MNK2 in regulating SREBP1 and lipid synthesis, providing new insights into TNBC BCBM. Inhibitors of MNK kinases, such as ETC-501, may offer potential in managing TNBC patients at high-risk for BCBM."

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

ETC-501, a novel brain penetrant MNK kinase inhibitor, potentiates TMZ-induced senescence and sensitizes glioblastoma cells to senolytic therapy (AACR 2025) - "Despite aggressive multimodal therapies, including maximal surgical resection, radiation, and temozolomide (TMZ) chemotherapy, recurrence is almost inevitable...Leveraging this enhanced senescence, we increased the susceptibility of GBM cells to the senolytic agent navitoclax, enabling targeted clearance of residual senescent cells. This "one-two punch" therapeutic strategy effectively eradicated cells that could otherwise act as reservoirs for recurrence. Our findings underscore the therapeutic potential of MNK inhibition in GBM, advancing our approach to managing GBM and potentially other malignancies characterized by senescence and SASP."

Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor